JP2009513586A - アミノ酸とヒアルロン酸ナトリウムを基にした眼科用医薬組成物 - Google Patents
アミノ酸とヒアルロン酸ナトリウムを基にした眼科用医薬組成物 Download PDFInfo
- Publication number
- JP2009513586A JP2009513586A JP2008536974A JP2008536974A JP2009513586A JP 2009513586 A JP2009513586 A JP 2009513586A JP 2008536974 A JP2008536974 A JP 2008536974A JP 2008536974 A JP2008536974 A JP 2008536974A JP 2009513586 A JP2009513586 A JP 2009513586A
- Authority
- JP
- Japan
- Prior art keywords
- sodium hyaluronate
- amino acids
- proline
- leucine
- glycine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920002385 Sodium hyaluronate Polymers 0.000 title claims abstract description 13
- 229940010747 sodium hyaluronate Drugs 0.000 title claims abstract description 13
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 title claims abstract description 9
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 12
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 8
- 206010013774 Dry eye Diseases 0.000 claims description 8
- 239000004471 Glycine Substances 0.000 claims description 8
- 229960003136 leucine Drugs 0.000 claims description 8
- 229960002429 proline Drugs 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 6
- 239000004395 L-leucine Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 239000000607 artificial tear Substances 0.000 claims description 6
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 4
- 229960003646 lysine Drugs 0.000 claims description 4
- 230000001575 pathological effect Effects 0.000 claims description 4
- 230000000472 traumatic effect Effects 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 3
- 229940024606 amino acid Drugs 0.000 claims description 3
- 239000003889 eye drop Substances 0.000 claims description 3
- 229940012356 eye drops Drugs 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 206010011026 Corneal lesion Diseases 0.000 claims 1
- 206010064996 Ulcerative keratitis Diseases 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 abstract description 2
- 238000001356 surgical procedure Methods 0.000 description 9
- 230000035876 healing Effects 0.000 description 5
- 210000000110 microvilli Anatomy 0.000 description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- 230000001172 regenerating effect Effects 0.000 description 4
- 230000004075 alteration Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 201000007717 corneal ulcer Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000002177 Cataract Diseases 0.000 description 2
- 208000028006 Corneal injury Diseases 0.000 description 2
- 229920002306 Glycocalyx Polymers 0.000 description 2
- 235000019454 L-leucine Nutrition 0.000 description 2
- 229930182821 L-proline Natural products 0.000 description 2
- 206010036346 Posterior capsule opacification Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 229960002449 glycine Drugs 0.000 description 2
- 210000004517 glycocalyx Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 210000003560 epithelium corneal Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000002430 laser surgery Methods 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本発明は、角膜上皮細胞に対し保護作用および再生作用を有する、アミノ酸とヒアルロン酸ナトリウムを基にした眼科用医薬組成物に関する。
流涙減少症(ドライアイ)治療薬はいまだ見いだされていない。ドライアイ症候群は、自然の涙液がもつ化学物理学的特性を備えた、洗浄、潤滑および消毒作用を有する点眼剤またはゲル剤(人口涙液)で治療される。
病理学的、外傷性、手術性またはパラサージカルの角膜損傷の場合、幾つかのアミノ酸とヒアルロン酸ナトリウムを配合すると、角膜上皮および間質組織の再構築プロセスの促進に特に効果があることが現在判明している。
a)グリシンとプロリン、
b)ヒアルロン酸ナトリウム、さらに場合によって
c)リジンとロイシン
の配合を含む眼科用医薬組成物に関する。
− グリシン 0.01〜0.5%
− L−プロリン 0.09〜0.06%
− ヒアルロン酸ナトリウム 0.5〜0.1%
さらに場合によって
− 塩酸L−リジン 0.01〜0.02%
− L−ロイシン 0.02〜0.005%。
− グリシン 0.1%
− L−プロリン 0.075%
− ヒアルロン酸ナトリウム 0.3%
さらに場合によって
− 塩酸L−リジン 0.014%
− L−ロイシン 0.011%。
純水30kgをL−プロリン、グリシン、リジンHCl、L−ロイシンおよび塩化ナトリウムと混合し、全成分が完全に溶解するまで撹拌する。
病理学的、外傷性、手術性またはパラサージカルの角膜損傷の場合における、角膜上皮および間質組織の再構築における本発明による人工涙液の保護効力および再生効力を調べた。
− 軽症、中等度または重症の涙液層の変質を患う患者50人の眼100(A群)
− レーザー手術(PRK)を受けた患者40人の眼80(B群)
− 再発性および/または持続性角膜潰瘍を患っている患者20人の眼20(C群)
− 白内障除去手術、すなわちIOL移植を伴う水晶体超音波乳化吸引術を受けた患者84人の眼84(D群)。
Claims (5)
- 活性成分として
a)グリシンとプロリン、
b)ヒアルロン酸ナトリウム、さらに場合によって
c)リジンとロイシン
の配合を含む、アミノ酸とヒアルロン酸ナトリウムを基にした眼科用医薬組成物。 - 種々の活性成分を以下に示す重量パーセンテージの範囲内で含む、請求項1に記載の組成物
− グリシン 0.01〜0.5%
− L−プロリン 0.09〜0.06%
− ヒアルロン酸ナトリウム 0.5〜0.1%
さらに場合によって
− 塩酸L−リジン 0.01〜0.02%
− L−ロイシン 0.02〜0.005%。 - 種々の活性成分を以下に示す重量パーセンテージで含む、請求項2に記載の組成物
− グリシン 0.1%
− L−プロリン 0.075%
− ヒアルロン酸ナトリウム 0.3%
さらに場合によって
− 塩酸L−リジン 0.014%
− L−ロイシン 0.011%。 - 病理学的、外傷性、手術性またはパラサージカルの角膜潰瘍化および病変ならびにドライアイの症状の治療用の、前記請求項に記載の組成物。
- 点眼剤、人口涙液、軟膏剤およびゲル剤の形態をした、前記請求項に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT002036A ITMI20052036A1 (it) | 2005-10-26 | 2005-10-26 | Composizioni farmaceutiche oftalmiche a base di amminoacidi e sodio ialuronato |
ITMI2005A002036 | 2005-10-26 | ||
PCT/EP2006/009967 WO2007048523A1 (en) | 2005-10-26 | 2006-10-16 | Ophthalmic pharmaceutical compositions based on amino acids and sodium hyaluronate |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009513586A true JP2009513586A (ja) | 2009-04-02 |
JP5312946B2 JP5312946B2 (ja) | 2013-10-09 |
Family
ID=37561156
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008536974A Active JP5312946B2 (ja) | 2005-10-26 | 2006-10-16 | アミノ酸とヒアルロン酸ナトリウムを基にした眼科用医薬組成物 |
Country Status (11)
Country | Link |
---|---|
US (2) | US20080249065A1 (ja) |
EP (1) | EP1940381B1 (ja) |
JP (1) | JP5312946B2 (ja) |
KR (1) | KR20080074107A (ja) |
AT (1) | ATE451916T1 (ja) |
CA (1) | CA2627215C (ja) |
DE (1) | DE602006011196D1 (ja) |
ES (1) | ES2335437T3 (ja) |
IT (1) | ITMI20052036A1 (ja) |
PL (1) | PL1940381T3 (ja) |
WO (1) | WO2007048523A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013500302A (ja) * | 2009-07-27 | 2013-01-07 | サンセベリノ,レナト | Uv−a線に対する眼球内部構造保護用又は経上皮架橋術式による円錐角膜の治療用点眼液 |
JP2013543862A (ja) * | 2010-11-08 | 2013-12-09 | ヒールオア・リミテッド | 眼科用緩衝組成物およびその使用方法 |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20052035A1 (it) * | 2005-10-26 | 2007-04-27 | Professional Dietetics Srl | Composizioni farmaceutiche cicatrizzanti sotto forma di crema a base di amminoacidi e sodio ialuronato |
ITMI20052037A1 (it) * | 2005-10-26 | 2007-04-27 | Professional Dietetics Srl | Composizioni farmaceutiche cicatrizzanti sotto forma di polvere sterile a base di amminoacidi e sodio ialuronato |
IT1396935B1 (it) | 2009-11-26 | 2012-12-20 | Solartium Entpr Ltd | Uso di una combinazione per il trattamento delle mucositi indotte da radiazioni o da chemioterapici |
IT1397522B1 (it) * | 2009-12-21 | 2013-01-16 | Solartium Entpr Ltd | Uso di una combinazione per il trattamento dell'osteoartrosi |
DE102010020940B4 (de) * | 2010-05-19 | 2014-09-25 | Heraeus Medical Gmbh | Antibiotische Beschichtung |
AT511164A1 (de) | 2011-03-03 | 2012-09-15 | Croma Pharma Gmbh | Verwendung eines viskoelastischen fluids zur herstellung eines medizinproduktes für die chirurgische behandlung des auges |
ITMI20110954A1 (it) * | 2011-05-26 | 2012-11-27 | Professional Dietetics Srl | Combinazioni per il trattamento delle mucositi vaginali o rettali |
ES2604816B1 (es) * | 2015-09-09 | 2018-01-29 | Farmalider, S.A. | Composición farmacéutica de tramadol para uso oftálmico |
IT201600116727A1 (it) * | 2016-11-18 | 2018-05-18 | Univ Politecnica Delle Marche | Composto per la guarigione di ferite |
JP7374986B2 (ja) | 2018-07-27 | 2023-11-07 | ジョンソン・アンド・ジョンソン・サージカル・ビジョン・インコーポレイテッド | 眼を治療するための組成物及び方法 |
US10966948B2 (en) | 2019-07-23 | 2021-04-06 | Johnson & Johnson Surgical Vision, Inc. | Compositions and methods for treating the eye |
US11969454B2 (en) | 2019-11-19 | 2024-04-30 | Johnson & Johnson Surgical Vision, Inc. | Compositions and methods for treating the eye |
US20230087388A1 (en) | 2020-02-28 | 2023-03-23 | Immunologik Gmbh | Inhibitors of human deubiquitinases for the treatment of coronaviral infections |
CN115515587A (zh) | 2020-04-27 | 2022-12-23 | 免疫学有限公司 | 用于治疗冠状病毒感染的6’-甲氧基辛可宁-9-醇类 |
IL298899A (en) | 2020-06-10 | 2023-02-01 | Metriopharm Ag | A compound for the treatment of corona virus infections |
EP3981405A1 (en) | 2020-10-08 | 2022-04-13 | MetrioPharm AG | Compound for the treatment of coronaviral infections |
WO2022042873A1 (en) | 2020-08-27 | 2022-03-03 | Immunologik Gmbh | Pharmaceutically acceptable lectins derived from plants, fungi and bacteria for the treatment of sars-cov-2 infections |
IT202100029726A1 (it) * | 2021-11-24 | 2023-05-24 | Professional Dietetics Spa | Composizioni oftalmiche per il trattamento di lesioni corneali |
EP4193994A1 (en) | 2021-12-08 | 2023-06-14 | MetrioPharm AG | Combination of 5-amino-2,3-dihydro-1,4-phtalazinedione and a 6'-methoxycinchonan-9-ol for use in the treatment of coronaviral infections |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6084225A (ja) * | 1983-10-17 | 1985-05-13 | Hiroko Shimizu | 点眼剤 |
JPH01238530A (ja) * | 1988-03-17 | 1989-09-22 | Seikagaku Kogyo Co Ltd | 角膜上皮層障害症治療剤 |
JPH0469342A (ja) * | 1990-07-06 | 1992-03-04 | Senju Pharmaceut Co Ltd | 水性医薬製剤 |
WO2004060348A2 (fr) * | 2002-12-26 | 2004-07-22 | Thorel Jean-Noel | Utilisation ophtalmique et ophtalmologique d’une base nutritive complexe en milieu aqueux |
WO2005084635A2 (en) * | 2004-03-02 | 2005-09-15 | Institute Of Ophthalmology | Pharmaceutical ocular preparations suitable for the treatment of the ocular surface and related disorders/diseases |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4707354A (en) * | 1985-06-17 | 1987-11-17 | Alpen Tau, Inc. | Mature skin treatment and protectant compositions and methods of using same |
WO1996003158A1 (en) * | 1994-07-22 | 1996-02-08 | Alcon Laboratories, Inc. | Use of low molecular weight amino acids in ophthalmic compositions |
US6541460B2 (en) * | 1996-08-07 | 2003-04-01 | George D. Petito | Method for use of hyaluronic acid in wound management |
JPH10290830A (ja) * | 1997-04-18 | 1998-11-04 | Ofutekusu:Kk | 眼手術用補助剤 |
US6645948B2 (en) | 1998-03-24 | 2003-11-11 | George D. Petito | Nutritional composition for the treatment of connective tissue |
US6620169B1 (en) * | 1999-08-26 | 2003-09-16 | Spineology Group, Llc. | Tools and method for processing and injecting bone graft |
US6654948B1 (en) * | 1999-10-12 | 2003-11-25 | International Business Machines Corporation | Methods and apparatus for partial and consistent monitoring of object-oriented programs and systems |
IT1318556B1 (it) * | 2000-06-07 | 2003-08-27 | Solartium Establishment | Composizione farmaceutica a base di prolina, glicina e lisina utilenella terapia per la cicatrizzazione delle ferite e delle lesioni |
ITTO20010804A1 (it) * | 2001-08-08 | 2003-02-08 | Professional Dietetics Srl | Composizioni a base di aminoacidi, idonee alla terapia per la cicatrizzazione e/o riparazione di ferite e lesioni, in particolare per l'appl |
US20040265268A1 (en) * | 2001-08-18 | 2004-12-30 | Deepak Jain | Compositions and methods for skin rejuvenation and repair |
US6780841B2 (en) * | 2001-11-13 | 2004-08-24 | Biocell Technology, Llc | Hyaluronic acid and chondroitin sulfate based hydrolyzed collagen type II and method of making same |
EP1379069A1 (de) * | 2002-07-02 | 2004-01-07 | Agfa-Gevaert AG | Vorrichtung und Verfahren zum Erfassen von Bildinformationen einer Bildvorlage |
EP1539193A4 (en) * | 2002-07-03 | 2010-05-05 | Pericor Science Inc | HYALURONIC ACID COMPOSITIONS AND METHODS OF USE |
US20040180025A1 (en) * | 2003-03-12 | 2004-09-16 | New Life Resources, Llc | Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations |
ITMI20052035A1 (it) * | 2005-10-26 | 2007-04-27 | Professional Dietetics Srl | Composizioni farmaceutiche cicatrizzanti sotto forma di crema a base di amminoacidi e sodio ialuronato |
ITMI20052037A1 (it) * | 2005-10-26 | 2007-04-27 | Professional Dietetics Srl | Composizioni farmaceutiche cicatrizzanti sotto forma di polvere sterile a base di amminoacidi e sodio ialuronato |
-
2005
- 2005-10-26 IT IT002036A patent/ITMI20052036A1/it unknown
-
2006
- 2006-10-16 KR KR1020087009861A patent/KR20080074107A/ko active Search and Examination
- 2006-10-16 EP EP06806304A patent/EP1940381B1/en active Active
- 2006-10-16 PL PL06806304T patent/PL1940381T3/pl unknown
- 2006-10-16 ES ES06806304T patent/ES2335437T3/es active Active
- 2006-10-16 JP JP2008536974A patent/JP5312946B2/ja active Active
- 2006-10-16 US US12/091,481 patent/US20080249065A1/en not_active Abandoned
- 2006-10-16 DE DE602006011196T patent/DE602006011196D1/de active Active
- 2006-10-16 WO PCT/EP2006/009967 patent/WO2007048523A1/en active Application Filing
- 2006-10-16 CA CA2627215A patent/CA2627215C/en active Active
- 2006-10-16 AT AT06806304T patent/ATE451916T1/de not_active IP Right Cessation
-
2010
- 2010-12-09 US US12/964,522 patent/US8524687B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6084225A (ja) * | 1983-10-17 | 1985-05-13 | Hiroko Shimizu | 点眼剤 |
JPH01238530A (ja) * | 1988-03-17 | 1989-09-22 | Seikagaku Kogyo Co Ltd | 角膜上皮層障害症治療剤 |
JPH0469342A (ja) * | 1990-07-06 | 1992-03-04 | Senju Pharmaceut Co Ltd | 水性医薬製剤 |
WO2004060348A2 (fr) * | 2002-12-26 | 2004-07-22 | Thorel Jean-Noel | Utilisation ophtalmique et ophtalmologique d’une base nutritive complexe en milieu aqueux |
WO2005084635A2 (en) * | 2004-03-02 | 2005-09-15 | Institute Of Ophthalmology | Pharmaceutical ocular preparations suitable for the treatment of the ocular surface and related disorders/diseases |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013500302A (ja) * | 2009-07-27 | 2013-01-07 | サンセベリノ,レナト | Uv−a線に対する眼球内部構造保護用又は経上皮架橋術式による円錐角膜の治療用点眼液 |
JP2013543862A (ja) * | 2010-11-08 | 2013-12-09 | ヒールオア・リミテッド | 眼科用緩衝組成物およびその使用方法 |
Also Published As
Publication number | Publication date |
---|---|
DE602006011196D1 (de) | 2010-01-28 |
ES2335437T3 (es) | 2010-03-26 |
EP1940381A1 (en) | 2008-07-09 |
ITMI20052036A1 (it) | 2007-04-27 |
EP1940381B1 (en) | 2009-12-16 |
ATE451916T1 (de) | 2010-01-15 |
US8524687B2 (en) | 2013-09-03 |
US20110077219A1 (en) | 2011-03-31 |
PL1940381T3 (pl) | 2010-05-31 |
WO2007048523A1 (en) | 2007-05-03 |
CA2627215A1 (en) | 2007-05-03 |
JP5312946B2 (ja) | 2013-10-09 |
KR20080074107A (ko) | 2008-08-12 |
US20080249065A1 (en) | 2008-10-09 |
CA2627215C (en) | 2015-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5312946B2 (ja) | アミノ酸とヒアルロン酸ナトリウムを基にした眼科用医薬組成物 | |
US7871646B2 (en) | Use of a human amniotic membrane composition for prophylaxis and treatment of diseases and conditions of the eye and skin | |
US20220332773A1 (en) | Silk-derived protein for treating inflammation | |
TW200930383A (en) | Methods and compositions for treating dry eye | |
KR20190008210A (ko) | 실크 유래 단백질을 이용한 상처 치료를 증가시키는 방법 | |
JPH11500032A (ja) | 生分解性眼シールド | |
JP5334584B2 (ja) | アミノ酸とヒアルロン酸ナトリウムを基にした滅菌粉末の形態の創傷治癒医薬組成物 | |
Isyaku | Treatment of pterygium | |
Aldavood et al. | Effect of acetylcysteine on experimental corneal wounds in dogs | |
RU2672564C2 (ru) | Способы лечения и предотвращения заболеваний глаз, расстройств и патологических состояний меланином и аналогами, предшественниками и производными меланина | |
JP6114182B2 (ja) | 角膜創傷治癒のためのケトロラク組成物 | |
WO2017030328A1 (ko) | 티모신 베타4 및 시트르산을 유효성분으로 포함하는 각막 손상 예방 또는 치료용 조성물 | |
WO1998013038A1 (fr) | Inhibiteur de turbidite sous-epitheliale | |
Hamal et al. | Amniotic membrane transplantation: Current indications in a tertiary eye hospital of eastern Nepal | |
RU2644701C1 (ru) | Способ консервативного лечения адаптированных проникающих ранений роговицы | |
Kim et al. | A rabbit model of conjunctival injection induction after strabismus surgery enhanced by topical application of irritant chemicals | |
Emerah | Clinical outcome of stream light Trans-PRK for correction of moderate to high Myopic Astigmatism | |
Higaki et al. | Corneal collagen shields for ocular drug delivery | |
Hong et al. | Efficiency and safety of human acellular dermal matrix for repair of leaking filtering blebs in rabbit eye | |
Gholipour et al. | Effect of dexamethasone in combination with acetylcysteine at different times on corneal wound healing in dogs | |
Ketring | The cornea of older dogs. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20091016 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101222 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20120509 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120515 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120509 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120815 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121016 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130115 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130122 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130214 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130221 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130314 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130322 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130618 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130703 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5312946 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |